Journal: iScience

Article Title: SEL1L-HRD1 ER-associated degradation suppresses hepatocyte hyperproliferation and liver cancer

doi: 10.1016/j.isci.2022.105183

Figure Lengend Snippet: WNT5A may link SEL1L-HRD1 ERAD to hepatic proliferation (A and B) Volcano plot (A) and tabular form (B) of proteomics data obtained via TMT-LC/MS analysis of hepatic ER isolated from 2- to 3-months-old mice (n = 3 per group). Lines mark p = value 0.05 (horizontal) or 2-fold changes (vertical). (C–F) Western blot analysis of ER and non-ER fractions from livers of 2-month-old mice (n = 3 per group) (C, black and red arrows mark WNT5A mobility shift), hepatocellular carcinoma and normal liver tissue from the DEN-HFD liver cancer model (n = 2 per group, 2 independent repeats) (D), livers of 10-week-old mice 48-h post partial hepatectomy (n = 3 per group) (E), livers from chronic CCL4 treatment (n = 2 per group) (F). (G) Western blot analysis normal liver and tumor tissues from the year-long-HFD experiment (n = 3 per group). (H and I) Hepatic cDNA microarray analyses of 9-week-old Sel1L Alb livers compared to Sel1L f/f livers: (H) KEGG pathway for Gene Set Enrichment Analysis (GSEA) from differentially expressed hepatic genes with p < 0.05 and fold change >1.29, and (I) Heatmap of proliferation-associated genes as a logarithm of fold change in Sel1L Alb and Hrd1 Alb livers as compared to Sel1L f/f and Hrd1 f/f livers, respectively (n = 3 per group). (J) Western blot analysis of HepG2 and Huh7 cells treated with 500 ng/mL recombinant WNT5A protein for 30 h (2 independent repeats). (K) Western blot analysis of Sel1L f/f and Sel1L Alb livers 2 weeks after i.v. injection of AAV8 expressing shRNA targeting Wnt5A or luciferase control (n = 2–3 per group). Quantitation shown below each blot. Calnexin, ER fraction control; HSP90, loading and non-ER controls. Values, mean ± SEM; ∗, p < 0.05; ∗∗, p < 0.01; ∗∗∗, p < 0.001 by Student’s t test.

Article Snippet: Human hepatocellular carcinoma tissue section microarray was obtained from US Biomax, Inc. (HLivH180Su14).

Techniques: Liquid Chromatography with Mass Spectroscopy, Isolation, Western Blot, Mobility Shift, Microarray, Recombinant, Injection, Expressing, shRNA, Luciferase, Quantitation Assay

Journal: iScience

Article Title: SEL1L-HRD1 ER-associated degradation suppresses hepatocyte hyperproliferation and liver cancer

doi: 10.1016/j.isci.2022.105183

Figure Lengend Snippet:

Article Snippet: Human hepatocellular carcinoma tissue section microarray was obtained from US Biomax, Inc. (HLivH180Su14).

Techniques: Western Blot, Plasmid Preparation, Microarray, Recombinant, Purification, Mutagenesis, Software, Expressing

Journal: bioRxiv

Article Title: Direct measurement of RNA Polymerase II hypertranscription in cancer FFPE samples

doi: 10.1101/2024.02.28.582647

Figure Lengend Snippet: Pathology classification, age and sex were provided by the vendor (BioChain). Each image spans the width of a standard charged microscope slide, where the tissue is visible under the paraffin skin. On-slide RNAPII-Ser5p FFPE-CUTAC was applied to slides in parallel, using a total of four slides each for 100 separate samples in all to produce the data analyzed in this study.

Article Snippet: The following pairs of human tumor and adjacent normal 5 μm tissue sections from single FFPE blocks were purchased from Biochain, Inc: Breast Normal/Tumor cat. no. T8235086PP/PT; Colon Normal/Tumor cat. no. T8235090PP/PT; Kidney Normal/Tumor cat. no. T8235142PP/PT; Liver Normal/Tumor cat. no. T8235149PP/PT; Lung Normal/Tumor cat. no. T8235152PP/PT; Rectum Normal/Tumor cat. no. T8235206PP/PT; Stomach Normal/Tumor cat. no. T8235248PP/PT.

Techniques: Microscopy